H6PD and heart failure: Therefore, the pharmacological compounds Bay 11–7082, parthenolide and DMF with their inhibitory effect on the G6PDH activity at non-toxic concentrations (Fig. 4a–c) should not only be considered for the evaluation of the long-term cardiovascular effects of G6PDH inhibition, but also for the treatment of patients suffering from NADPH-superoxide anion associated heart failure.